How Often Are FFP Infusions Given for Leiner's Disease?

Seeing your baby hooked up to machines to receive blood products is terrifying, but understanding the process can help you feel more prepared. During an acute flare of Leiner’s disease, Fresh Frozen Plasma (FFP) infusions are often given frequently—sometimes daily or several times a week—to rapidly supply the missing complement proteins your baby’s immune system needs. However, there is no single “standard” schedule that applies to every infant ^[1]. The exact frequency is highly individualized based on how sick the baby is and how quickly their body responds. The reassuring news is that this intensive schedule is temporary; as your baby stabilizes, the infusions are gradually spaced out and eventually stopped.

The Acute Schedule and What to Expect

Leiner’s disease is historically linked to a dysfunction or deficiency in the complement system, specifically a protein called C5 ^[2]. The complement system is a part of the immune system that helps the body fight infections and clear away damaged cells. Because a baby with Leiner’s disease may not make functional C5 proteins, FFP is used as a replacement therapy to deliver healthy, working complement proteins directly into their bloodstream ^[3].

To spare your baby from being poked with a needle every day, doctors will typically place a semi-permanent IV, such as a PICC line or central line. FFP infusions generally take between 1 and 2 hours to complete. During this time, the plasma drips slowly into the line, and you are usually encouraged to hold, feed, and comfort your baby.

Note: Because the severe symptoms of Leiner’s disease (widespread skin peeling, diarrhea, failure to thrive) can look identical to other severe immune conditions—like Severe Combined Immunodeficiency (SCID) or Omenn syndrome—doctors will also run broader genetic panels to confirm the diagnosis, as those conditions require different treatments.

Monitoring C3, C5, and Complement Levels

To figure out exactly how often your baby needs an infusion, doctors actively monitor specific markers in your baby’s blood to ensure the treatment is working.

• Targeting the missing proteins: The medical team will draw blood to check the levels of individual complement proteins, such as C3 and C5 ^[4]. These tests show how much of the necessary protein is circulating in the blood.
• Checking the system’s function: They also use a functional test called a CH50 assay ^[5]. This test measures how well the entire complement pathway is working together as a team. If the CH50 level is low, it indicates that the FFP hasn’t fully corrected the defect, and the baby might need infusions more frequently to reach a safe baseline ^[6].

By closely watching these numbers alongside your baby’s physical symptoms, doctors can tailor the therapy. This ensures the baby gets enough plasma to heal without receiving unnecessary extra fluids ^[7].

The Weaning Process and Long-Term Care

FFP is a vital, lifesaving bridge during a crisis, but it is not meant to be a permanent, everyday treatment. Receiving large volumes of plasma frequently puts stress on a small baby’s body and carries risks, such as Transfusion-Associated Circulatory Overload (TACO) (when the body has too much fluid to pump effectively) and Transfusion-Related Acute Lung Injury (TRALI) ^[8][9].

Because of these risks, the primary goal is always to reduce the infusions as soon as it is safe to do so ^[9]. Once the acute symptoms subside—meaning the skin barrier begins to heal, infections are controlled, and the baby starts to gain weight—the care team will initiate the weaning process. They will slowly space out the infusions from daily, to a few times a week, to weekly, until the acute treatments are stopped entirely.

However, weaning off FFP does not mean the underlying condition is cured. Genetic complement deficiencies are lifelong. After the FFP is stopped, your baby will transition to a long-term preventative care plan, which typically includes prophylactic antibiotics and specialized vaccination schedules to protect against recurrent infections.